These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 37141329)
1. Weight loss efficiency and safety of tirzepatide: A Systematic review. Lin F; Yu B; Ling B; Lv G; Shang H; Zhao X; Jie X; Chen J; Li Y PLoS One; 2023; 18(5):e0285197. PubMed ID: 37141329 [TBL] [Abstract][Full Text] [Related]
2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691 [TBL] [Abstract][Full Text] [Related]
3. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Cai W; Zhang R; Yao Y; Wu Q; Zhang J Front Public Health; 2024; 12():1277113. PubMed ID: 38356942 [TBL] [Abstract][Full Text] [Related]
4. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Nauck MA; D'Alessio DA Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763 [TBL] [Abstract][Full Text] [Related]
5. Tirzepatide: A Review in Type 2 Diabetes. France NL; Syed YY Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable? Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes. De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681 [TBL] [Abstract][Full Text] [Related]
11. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Bradley CL; McMillin SM; Hwang AY; Sherrill CH Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094 [TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723 [TBL] [Abstract][Full Text] [Related]
13. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials. Ayesh H; Suhail S; Ayesh S; Niswender K Diabetes Obes Metab; 2024 Sep; 26(9):3801-3809. PubMed ID: 38923379 [TBL] [Abstract][Full Text] [Related]
15. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Frías JP Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356 [TBL] [Abstract][Full Text] [Related]
16. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
17. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. Permana H; Yanto TA; Hariyanto TI Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410 [TBL] [Abstract][Full Text] [Related]
20. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]